Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry

Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine whether the body mass index (BMI) is involved in the response to rituximab in rheumatoid arthritis (RA). Materials and methods: This multicenter retrospective study included 206 RA patients who received rituximab from the Turkish Biologic (TURKBIO) registry between 2011 and the end of May 2017. Demographic and clinical data including age, sex, disease type, disease duration, and previous or current treatment with disease-modifying antirheumatic drugs (DMARDs) and biological drug durations are stored in the database. Patients with a BMI ≥30 kg/m2 were classified as obese, and patients with a BMI <30 kg/m2 were classified as nonobese. Kaplan-Meier survival analysis was performed to estimate the drug survival. The subgroups were compared using the log-rank test. Results: The mean BMI of 206 patients included in the study was 27.05 (17.2–43.4) kg/m2. There were 59 (28.6%) patients in the obese group and 147 (71.4%) patients in the nonobese group. The mean age, female percentage, and baseline disease activity score 28 (DAS28) were higher in the obese group than in the nonobese group. However, the ΔDAS28 at both 6 and 12 months were not significantly different between the groups (p = 0.785 and p = 0.512, respectively). Patient pain Visual Analogue Scale (VAS), patient fatigue VAS, and patient global VAS scores were also significantly higher at baseline in the obese group (p = 0.003, p = 0.006, and p = 0.006, respectively). However, no significant difference was found in terms of changes in patient pain VAS, patient fatigue VAS, patient global VAS and physician global VAS scores at 6 and 12 months compared to those at baseline. Rituximab treatment was ongoing for 71.2% of the obese and 63.3% of the nonobese patients (p = 0.279). The median drug survival duration was 77 months in the obese group and 62 months in the nonobese group (p = 0.053). The estimated drug survival rates for rituximab were not statistically significantly different in the obese and nonobese groups. Rituximab-related side effects were also similar between the groups. Conclusion: In obese and nonobese patients with RA, rituximab treatment exhibits similar side effects and similar long-term efficacy. These results suggest that obesity does not alter drug survival for rituximab and response rates, in RA and rituximab may be a favorable treatment agent in patients with RA and obesity.

Anahtar Kelime: Body mass index drug survival obesity rheumatoid arthritis rituximab

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body- mass index and mortality in a prospective cohort of U.S. adults. The New England Journal of Medicine 1999; 341 (15): 1097- 1105. https://doi.org/10.1056/NEJM199910073411501
2. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. The New England Journal of Medicine 2006; 355 (8): 763-778. https://doi.org/10.1056/ NEJMoa055643
3. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT et al. The global obesity pandemic: Shaped by global drivers and local environments. Lancet 2011; 378 (9793): 804-814. https:// doi.org/10.1016/S0140-6736(11)60813-1
4. OuchiN,ParkerJL,LugusJJ,WalshK.Adipokinesininflammation and metabolic disease. Nature Reviews Immunology 2011; 11 (2): 85-97. https://doi.org/10.1038/nri2921
5. Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: The additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Medical Weekly 2011; 141: 13211. https://doi.org/10.4414/smw.2011.13211
6. Hauner H. Secretory factors from human adipose tissue and their functional role. The Proceedings of the Nutrition Society 2005; 64 (2): 163-169. https://doi.org/10.1079/PNS2005428
7. Iannone F, Fanizzi R, Notarnicola A, Scioscia C, Anelli MG et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients. Joint Bone Spine 2015; 82 (3): 187-191. https://doi. org/10.1016/j.jbspin.2014.12.006
8. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev- Petersen K et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Research & Therapy 2008; 10 (2): R30. https://doi. org/10.1186/ar2383
9. Armstrong DJ, McCausland EM, Quinn AD, Wright GD. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology 2006; 45 (6): 782-783. https://doi.org/10.1093/ rheumatology/kel124
10. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5 (5): 525-532.
11. Bartfai T, Waalen J, Buxbaum JN. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? The Journal of Rheumatology 2007; 34 (3): 488-492.
12. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Annals of Rheumatic Diseases 2008; 67 (6): 769-774. https://doi.org/10.1136/ard.2007.078832
13. García-Poma A, Segami MI, Mora CS, Ugarte MF, Terrazas HN et al. Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clinical Rheumatology 2007; 26 (11): 1831-1835. https://doi. org/10.1007/s10067-007-0583-4
14. Crowson CS, Matteson EL, Davis JM, 3rd, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care and Research 2013; 65 (1): 71-77. https://doi.org/10.1002/acr.21660
15. Lahiri M, Luben RN, Morgan C, Bunn DK, Marshall T et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register--the EPIC-2-NOAR Study). Annals of Rheumatic Diseases 2014; 73 (1): 219-226. https://doi. org/10.1136/annrheumdis-2012-202481
16. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P et al. Rheumatoid arthritis. Nature Reviews Disease Primers 2018; 4: 18001. https://doi.org/10.1038/nrdp.2018.1
17. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Annals of Rheumatic Diseases 2015; 74 (2): 415-421. https://doi.org/10.1136/annrheumdis-2013-204021
18. Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Annals of Rheumatic Diseases 2005; 64 (4): 77-80. https://doi.org/10.1136/ard.2005.042507
19. Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi- Monadi S et al. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clinical Rheumatology 2019; 38 (11): 2977-2994. https://doi.org/10.1007/s10067-019-04699-8
20. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clinical Pharmacokinetics 2010; 49 (2): 71-87. https://doi. org/10.2165/11318100-000000000-00000
21. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B et al. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care and Research 2013; 65 (1): 94-100. https://doi.org/10.1002/acr.21768
22. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis and Rheumatism 2011; 63 (2): 359-364. https://doi.org/10.1002/art.30136
23. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism 2010; 62 (9): 2569-2581. https://doi.org/10.1002/art.27584
24. Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: A prospective cohort study. Annals of Rheumatic Diseases 2014; 73 (11): 1914-1922. https://doi. org/10.1136/annrheumdis-2014-205459
25. Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Annals of Rheumatic Diseases 2014; 73 (11): 2029-2033.https:// doi.org/10.1136/annrheumdis-2013-205094
26. Colmegna I, Hitchon CA, Bardales MC, Puri L, Bartlett SJ. High rates of obesity and greater associated disability among people with rheumatoid arthritis in Canada. Clinical Rheumatology 2016; 35 (2): 457-460. https://doi.org/10.1007/s10067-015- 3154-0
27. Somers TJ, Wren AA, Blumenthal JA, Caldwell D, Huffman KM et al. Pain, physical functioning, and overeating in obese rheumatoid arthritis patients: Do thoughts about pain and eating matter? Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases 2014; 20 (5): 244-250. https://doi.org/10.1097/RHU.0000000000000124
28. Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F et al. Adipokines and inflammation: is it a question of weight? British Journal of Pharmacology 2018; 175 (10): 1569-1579. https:// doi.org/10.1111/bph.14181
29. Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S et al. Obesity reduces the real-world effectiveness of cytokine- targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology 2020; 59 (8): 1916-1926. https://doi.org/10.1093/rheumatology/kez535
30. Pers YM, Godfrin-Valnet M, Lambert J, Fortunet C, Constant E et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. The Journal of Rheumatology 2015; 42 (4): 580-584. https://doi.org/10.3899/ jrheum.140673
31. Gardette A, Ottaviani S, Sellam J, Berenbaum F, Lioté F et al. Body mass index and response to tocilizumab in rheumatoid arthritis: A real life study. Clinical Rheumatology 2016; 35 (4): 857-861. https://doi.org/10.1007/s10067-016-3183-3
32. Crouch M, Guesdon W, Shaikh S. Obesity suppresses B cell development and impairs antibody production upon antigen challenge. The FASEB Journal 2017; 31: 964-967. https://doi. org/10.1096/fasebj.31.1_supplement.964.7
33. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018; 13 (5): 0195123. https://doi.org/10.1371/journal. pone.0195123
34. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Annals of Rheumatic Diseases 2015; 74 (5): 813-817. https://doi.org/10.1136/annrheumdis-2013-204448
35. Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Research and Therapy 2012; 14 (3): R115. https://doi.org/10.1186/ar3841
36. Ottaviani S, Gardette A, Roy C, Tubach F, Gill G et al. Body Mass Index and response to rituximab in rheumatoid arthritis. Joint Bone Spine 2015 ;82 (6): 432-436. https://doi.org/10.1016/j. jbspin.2015.02.011

APA	KARATAŞ A, Pişkin Sağır R, Koca S, Dalkılıç E, can g, PEHLIVAN Y, Yazici A, Inanc N, Cefle A, Ertürk Z, Akar S, SENEL A, Birlik M, Akkoç N, Onen F (2023). Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. , 1321 - 1329. 10.55730/1300-0144.5698
Chicago	KARATAŞ AHMET,Pişkin Sağır Rabia,Koca Suleyman Serdar,Dalkılıç Ediz,can gercek,PEHLIVAN YAVUZ,Yazici Ayten,Inanc Nevsun,Cefle Ayse,Ertürk Zeynep,Akar Servet,SENEL ABDURRAHMAN SONER,Birlik Merih,Akkoç Nurullah,Onen Fatos Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. (2023): 1321 - 1329. 10.55730/1300-0144.5698
MLA	KARATAŞ AHMET,Pişkin Sağır Rabia,Koca Suleyman Serdar,Dalkılıç Ediz,can gercek,PEHLIVAN YAVUZ,Yazici Ayten,Inanc Nevsun,Cefle Ayse,Ertürk Zeynep,Akar Servet,SENEL ABDURRAHMAN SONER,Birlik Merih,Akkoç Nurullah,Onen Fatos Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. , 2023, ss.1321 - 1329. 10.55730/1300-0144.5698
AMA	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. . 2023; 1321 - 1329. 10.55730/1300-0144.5698
Vancouver	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. . 2023; 1321 - 1329. 10.55730/1300-0144.5698
IEEE	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F "Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry." , ss.1321 - 1329, 2023. 10.55730/1300-0144.5698
ISNAD	KARATAŞ, AHMET vd. "Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry". (2023), 1321-1329. https://doi.org/10.55730/1300-0144.5698

APA	KARATAŞ A, Pişkin Sağır R, Koca S, Dalkılıç E, can g, PEHLIVAN Y, Yazici A, Inanc N, Cefle A, Ertürk Z, Akar S, SENEL A, Birlik M, Akkoç N, Onen F (2023). Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish Journal of Medical Sciences, 53(5), 1321 - 1329. 10.55730/1300-0144.5698
Chicago	KARATAŞ AHMET,Pişkin Sağır Rabia,Koca Suleyman Serdar,Dalkılıç Ediz,can gercek,PEHLIVAN YAVUZ,Yazici Ayten,Inanc Nevsun,Cefle Ayse,Ertürk Zeynep,Akar Servet,SENEL ABDURRAHMAN SONER,Birlik Merih,Akkoç Nurullah,Onen Fatos Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish Journal of Medical Sciences 53, no.5 (2023): 1321 - 1329. 10.55730/1300-0144.5698
MLA	KARATAŞ AHMET,Pişkin Sağır Rabia,Koca Suleyman Serdar,Dalkılıç Ediz,can gercek,PEHLIVAN YAVUZ,Yazici Ayten,Inanc Nevsun,Cefle Ayse,Ertürk Zeynep,Akar Servet,SENEL ABDURRAHMAN SONER,Birlik Merih,Akkoç Nurullah,Onen Fatos Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish Journal of Medical Sciences, vol.53, no.5, 2023, ss.1321 - 1329. 10.55730/1300-0144.5698
AMA	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish Journal of Medical Sciences. 2023; 53(5): 1321 - 1329. 10.55730/1300-0144.5698
Vancouver	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry. Turkish Journal of Medical Sciences. 2023; 53(5): 1321 - 1329. 10.55730/1300-0144.5698
IEEE	KARATAŞ A,Pişkin Sağır R,Koca S,Dalkılıç E,can g,PEHLIVAN Y,Yazici A,Inanc N,Cefle A,Ertürk Z,Akar S,SENEL A,Birlik M,Akkoç N,Onen F "Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry." Turkish Journal of Medical Sciences, 53, ss.1321 - 1329, 2023. 10.55730/1300-0144.5698
ISNAD	KARATAŞ, AHMET vd. "Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry". Turkish Journal of Medical Sciences 53/5 (2023), 1321-1329. https://doi.org/10.55730/1300-0144.5698